CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 169 enrolled
Drug / intervention
Restylane Perlane Lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03097783
NCT03097783N/ACompleted
CompareCT.gov

A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Efficacy and Safety of Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Galderma R&D·interventional·Posted Mar 31, 2017·Updated Nov 3, 2023

In Brief

A clinical study evaluating Restylane Perlane Lidocaine for Midface Volume Deficit. Completed, enrolled 169 participants across 1 site.

Detailed Summary

This is a randomized, multi-center, evaluator-blinded, no-treatment controlled study to evaluate the efficacy and safety of Restylane Perlane Lidocaine for correction of Midface Volume Deficit and/or Midface Contour Deficiency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMidface Volume Deficit
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 31, 2017
Enrollment StartApr 26, 2017
Primary CompletionMar 23, 2018
Study CompletionSep 14, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.3 years ago

Interventions

Restylane Perlane Lidocainedevice

Intradermal injection